Imported mucocutaneous leishmaniasis in New York City. Report of a patient treated with amphotericin B.
A case of mococutaneous leishmaniasis in a patient referred to Memorial Sloan-Kettering Cancer Center, New York, with a presumptive diagnosis of lethal mid-line granuloma is described. The patient had lived in Bolivia and had been treated with antimony during and after which his mucosal lesions progressed. These lesions completely healed with 971 mg of amphotericin B. Mucocutaneous leishmaniasis is endemic in many areas of Central and South America and may occur in patients in the United States who have lived in or traveled to these areas. Organisms may be difficult to identify, and multiple biopsies and cultures may be necessary. The use of amphotericin B for the treatment of leishmaniasis is reviewed. It is an effective alternative to antimony therapy, and in some cases resistant to antimony, it may be the drug of choice.
D000328:Adult; D000606:Amino Sugars / Q000627:therapeutic use; D000666:Amphotericin B / Q000627:therapeutic use*; D000965:Antimony / Q000627:therapeutic use; D001838:Bolivia; D003937:Diagnosis, Differential; D006103:Granuloma, Lethal Midline / Q000175:diagnosis; D006801:Humans; D007897:Leishmaniasis, Mucocutaneous / Q000175:diagnosis / Q000188:drug therapy* / Q000453:epidemiology; D008297:Male; D009519:New York City; D014195:Travel
D000606:Amino Sugars; D000666:Amphotericin B; D000965:Antimony